Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.47USD
14 Dec 2018
Change (% chg)

$-0.03 (-5.39%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.50
Day's Low
$0.47
Volume
9,813
Avg. Vol
20,432
52-wk High
$2.35
52-wk Low
$0.47

Summary

Name Age Since Current Position

Steven Kriegsman

2018 Chairman of the Board, Chief Executive Officer

Eric Curtis

50 2018 President, Chief Operating Officer

John Caloz

64 2009 Chief Financial Officer

David Haen

37 2007 Vice President - Business Development

Olivia Ware

2016 Chief Commercial Officer

Earl Brien

56 2016 Director

Joel Caldwell

62 2017 Director

Louis Ignarro

73 2002 Independent Director

Michelle Carroll

2015 IR Contact Officer
» Insider Trading

Biographies

Name Description

Steven Kriegsman

Mr. Steven A. Kriegsman is Chairman of the Board, Chief Executive Officer of CytRx Corporation. He has been CytRx’s Chairman and Chief Executive Officer since October 2014. Prior to that, he served as CytRx’s President and Chief Executive Officer and a director since July 2002. He also serves as a director of Galena Biopharma, a listed public company, and is a member of its Compensation and its Strategy Committees. Mr. Kriegsman also serves on the Board of Directors of Catasys, Inc. He previously served as Director and Chairman of Global Genomics from June 2000 until 2002. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. During his career, he has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. In the past five years, Mr. Kriegsman has also served on the board of directors of Bradley Pharmaceuticals, Inc. and Hythiam, Inc. Mr. Kriegsman has a B.S. degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors’ College

Eric Curtis

Mr. Eric L. Curtis is President, Chief Operating Officer of the company. He brings 25 years of life science development and operational experience to CytRx, with a proven track record in oncology and orphan diseases. Mr. Curtis will assume a leadership role in the partnering of CytRx's proprietary LADR™ technology and advancing the Company's current programs and future discoveries. Mr. Curtis holds a Master of Business Administration degree from Pennsylvania State University. He earned his Bachelor of Science degree in both Business and Psychology, from the University of Pittsburgh.

John Caloz

Mr. John Y. Caloz is no longer Chief Financial Officer of CytRx Corporation effective December 31, 2018. Mr. Caloz was named Chief Financial Officer. He was Chief Accounting Officer of the company. He has a history of providing senior financial leadership in the life sciences sector, as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Professional Accountant and Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.

David Haen

Mr. David J. Haen is Vice President – Business Development of Cytrx Corporation. From 1999 to 2003, Mr. Haen worked as an associate for Kriegsman Capital Group LLC, a financial advisory firm focused on emerging companies in the life sciences field. Mr. Haen received a B.A. in Communications and Business from Loyola Marymount University.

Olivia Ware

Ms. Olivia C. Ware is Chief Commercial Officer of the Company. While at Genentech, Ms. Ware was a Senior Director of Oncology and was responsible for the initial commercial launch of Avastin in the U.S., which reached $1 billion in sales during its first year on the market. Prior to this, she was head of Herceptin marketing and held a number of other positions in the commercial organization. Later, Ms. Ware was a Senior Director in the Product Portfolio Management Group, managing approximately 20 senior leaders responsible for building and leading the cross-functional drug development teams that developed and implemented strategic plans and guided the drug development processes for all oncology products at Genentech. Since leaving Genentech, Ms. Ware has worked as an independent consultant providing strategic support and management expertise for global product launches, market assessments and coaching and mentoring for team leaders and executive teams. Prior to Genentech, Ms. Ware worked in healthcare consulting for Baxter Healthcare; and was the western region general manager for a large national home healthcare company. She has an MBA in Finance and Marketing, from the University of North Carolina at Chapel Hill and a B.A. from Davidson College.

Earl Brien

Dr. Earl W. Brien, M.D. serves as Director of the Company. Dr. Brien currently serves as a Professor of Orthopedic Surgery and Surgical Director of the Sarcoma Service at Cedars Sinai Medical Center in Los Angeles, California. Dr. Brien earned his medical degree from Howard University School of Medicine, Washington, D.C., and completed fellowships in Orthopedic Oncology at the Memorial Sloan-Kettering Cancer Center, New York, New York, and in Metabolic Bone Disease at the Hospital for Special Surgery at Cornell University, also in New York, New York. He is the recipient of numerous grants, with an extensive bibliography of peer-reviewed articles to his credit spanning more than twenty years. Our board of directors believes that Dr. Brien is highly qualified to serve as a member of the board because of his unique perspective as both a sarcoma surgeon and a collaborator with treating sarcoma physicians and as a strategic advisor to biotech and medical device companies.

Joel Caldwell

Mr. Joel Caldwell has been appointed as Director of the Company., effective July 12, 2017. He brings more than 30 years of experience in tax matters, finance and internal auditing. He retired from Southern California Edison, one of the nation's largest public utilities, where he had been employed for 28 years in various executive-level accounting and finance positions covering Internal Audits, Executive Compensation, Long Term Finance, Employee Benefits and, most recently prior to his retirement, Sarbanes-Oxley Internal Controls Compliance. He also worked in public accounting at the firm of Arthur Andersen & Co. Mr. Caldwell volunteers his business skills, serving as a financial advisor on the board of trustees of a charitable organization, and continues his involvement with track and field sports by volunteering as a meet official at Pacific Palisades Charter High School. Mr. Caldwell holds B.S. and M.B.A. degrees from the University of California, Berkeley. He has been a Certified Public Accountant in California since 1982 and a Certified Internal Auditor since 1986. Mr. Caldwell is a member of both the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants.

Louis Ignarro

Dr. Louis J. Ignarro, Ph.D., is Independent Director of CytRx Corporation. He previously served as a director of Global Genomics since November 20, 2000. Dr. Ignarro serves as the Jerome J. Belzer, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. Dr. Ignarro has been at the UCLA School of Medicine since 1985 as a professor, acting chairman and assistant dean. Dr. Ignarro received the Nobel Prize for Medicine in 1998. Dr. Ignarro received a B.S. in pharmacy from Columbia University and his Ph.D. in Pharmacology from the University of Minnesota.

Michelle Carroll

Basic Compensation

Name Fiscal Year Total

Steven Kriegsman

2,191,700

Eric Curtis

--

John Caloz

751,000

David Haen

--

Olivia Ware

--

Earl Brien

--

Joel Caldwell

--

Louis Ignarro

--

Michelle Carroll

--
As Of  31 Dec 2014

Insider Trading

Name Shares Traded Price

Kriegsman (Steven A)

 387,597 $1.75

Kriegsman (Steven A)

 2,325,581 $0.43
» Full list on Insider Trading